FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.

ScopeUp collects Ontario and national pharmacy practice updates and links every item to its source. Verify details against the source document before changing workflows.